Medicine and Dentistry
Spinal Muscular Atrophy
100%
Ataxia Telangiectasia
70%
Disease
48%
Sodium Valproate
18%
Pediatrics
17%
Clinical Trial
15%
Carnitine
14%
Transverse Myelitis
14%
Placebo
14%
Axon
13%
Adverse Event
13%
Diagnosis
12%
Weakness
12%
Werdnig Hoffmann Disease
11%
Motor Performance
11%
Newborn Screening
10%
Neuromuscular Disease
10%
Cancer
9%
Nusinersen
9%
Myasthenia gravis
9%
Neuromuscular Junction Disorder
9%
Botulism
9%
Muscular Dystrophy
9%
Duchenne Muscular Dystrophy
9%
Neurologic Disease
9%
Immune Deficiency
8%
Compound Muscle Action Potential
8%
Infection
7%
Scoliosis
7%
Neurofilament
7%
Clinical Feature
7%
Disease Course
7%
Malignant Neoplasm
7%
Silo-Filler's Disease
6%
Autosomal Recessive Disorder
6%
Respiratory Failure
6%
Lung Function
6%
Acute Disseminated Encephalomyelitis
6%
Rehabilitation Engineering
6%
Kinesin
6%
Small Nuclear Ribonucleoprotein
6%
Neuropathology
6%
Artificial Respiration
5%
Injury
5%
Exome Sequencing
5%
Action Potential Amplitude
5%
Prevalence
5%
Limb
5%
Skin Biopsy
5%
Emergency Care
5%
Keyphrases
Spinal muscular Atrophy
91%
Ataxia Telangiectasia
81%
Neurofilament
30%
Neuromuscular Disease
23%
Newborn Screening
15%
Axon
14%
Survival Motor Neuron
13%
Motor Neuron
13%
Nusinersen
13%
Clinical Trials
12%
Neuropathology
12%
Axon Diameter
11%
Autosomal Recessive
10%
SMN2
10%
Radial Growth
10%
Clinical Course
9%
Acute Flaccid Myelitis
9%
Laminin-2
9%
NF-H
9%
Valproic Acid
9%
Copy number
9%
Older Adults
9%
Duchenne muscular Dystrophy
9%
Transient Receptor Potential Vanilloid 4 (TRPV4)
9%
Neurodegenerative Diseases
8%
Nerve
8%
Hammersmith Functional Motor Scale Expanded (HFMSE)
8%
Motor Axon
8%
Spinal Cord
7%
Myelin-associated Glycoprotein
7%
Pediatric
7%
SMN1 Gene
7%
Motor Function
7%
SMN2 Copy number
7%
Amyotrophic Lateral Sclerosis
7%
Neuropathy
7%
ATM mutation
7%
Compound muscle Action Potential
7%
Clinical Trial Design
6%
Infantile Onset
6%
Missense mutation
6%
Standard of Care
6%
Congenital muscular Dystrophy
6%
Disease Burden
6%
Pulmonary Disease
6%
Neurological Examination
6%
Clinical Characteristics
6%
Ataxia Telangiectasia mutated
6%
Biopsy Specimen
6%
Muscular Dystrophy
5%
Neuroscience
Ataxia Telangiectasia
70%
Spinal Muscular Atrophy
54%
Axon
43%
Neurofilament
39%
Motor Neuron
37%
Peripheral Neuropathy
30%
Myelin
19%
Myelin Associated Glycoprotein
16%
Muscular Dystrophy
15%
Eye Movement
13%
Survival Motor Neuron Protein
11%
Myelinogenesis
11%
Saccade
10%
Wallerian Degeneration
9%
Metabolic Pathway
9%
Ganglioside
9%
Sarcoglycan
9%
Valproic Acid
9%
Transverse Myelitis
9%
Myelitis
9%
Nerve Fiber
9%
Peripheral Nervous System
9%
Basal Ganglia
8%
Ataxia
7%
Protein Quaternary Structure
7%
Autosomal Recessive Disorder
6%
Neuromuscular Disorder
6%
Telangiectasia
6%
Neurodegenerative Disorder
6%
Nervous System
6%
Carnitine
6%
Acute Disseminated Encephalomyelitis
6%
Polyneuropathy
6%
Tremor
6%
Intrathecal
6%
Axoplasm
6%
Motor Unit
6%
Nerve Fiber Degeneration
6%
Myoclonus
6%
Protein Expression
6%
Missense Mutation
5%
Magnetic Resonance Imaging
5%
Sensory Nerve
5%
Afferent Nerve Fiber
5%
Neuromuscular
5%
ATM Protein
5%
Neuromuscular Junction
5%
Disinhibition
5%
Nerve Cell Degeneration
5%
